Artificial intelligence platform demonstrates high adherence in patients receiving fixed-dose ledipasvir and sofosbuvir: A pilot study

Alain H. Litwin, Laura Shafner, Brianna Norton, Matthew J. Akiyama, Linda Agyemang, Mercedes Guzman, Tatiana Vera, Moonseong Heo

Research output: Contribution to journalArticlepeer-review

Abstract

This study evaluated health outcomes among people who inject drugs who are infected with hepatitis C virus using an artificial intelligence platform. Mean (SD) cumulative adherence (visual confirmation of administration) was 91.3% (10.5%). Most subjects (88.2%) achieved ≥80% adherence to treatment, and 88.2% (15 of 17) achieved a sustained virologic response.

Original languageEnglish (US)
Article numberofaa290
JournalOpen Forum Infectious Diseases
Volume7
Issue number8
DOIs
StatePublished - Aug 1 2020

Keywords

  • Adherence
  • HCV
  • PWID

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Artificial intelligence platform demonstrates high adherence in patients receiving fixed-dose ledipasvir and sofosbuvir: A pilot study'. Together they form a unique fingerprint.

Cite this